Venâncio Avancini Ferreira Alves

Venâncio Avancini Ferreira Alves

Auto-generated profile, based on publicly available information

Venâncio Avancini Ferreira Alves

Department of Pathology, University of São Paulo School of Medicine, CICAP, Pathology, Hospital Alemao Oswaldo Cruz, São Paulo, SP, Brazil

Research Focus & Metrics

Academic Career Length

41Years (1986-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 January 2008 in Virchows Archiv
Verified
Journal Article
Closed access
PDF file
CPCéline Pinheiro
Céline Pinheiro
ALAdhemar Longatto-Filho
Adhemar Longatto-Filho
CSCristovam Scapulatempo-Neto
Cristovam Scapulatempo-Neto
LFLuísa Ferreira
Luísa Ferreira
SMSandra Martins
Sandra Martins
FBFatima Baltazar
Fatima Baltazar

1 July 2015 in Progress in Lipid Research
Verified
Journal Article
Closed access
JWJoost Willebrords
Joost Willebrords
IPIsabel Veloso Alves Pereira
Isabel Veloso Alves Pereira
MMMichaël Maes
Michaël Maes
SYSara Crespo Yanguas
Sara Crespo Yanguas
ICIsabelle Colle
Isabelle Colle
Mathieu VinkenMathieu Vinken
Mathieu Vinken

10 November 2017 in Frontiers in Medicine
Verified
Journal Article
Open access
SMSebastiao N. Martins-Filho
Sebastiao N. Martins-Filho
CPCaterina Paiva
Caterina Paiva
RARaymundo Soares Azevedo
Raymundo Soares Azevedo
VAVenancio Avancini Ferreira Alves
Venancio Avancini Ferreira Alves
Background: Histological grading typically reflects the biological behavior of solid tumors, thus providing valuable prognostic information. This is also expected in Hepatocellular Carcinoma (HCC), although limited access to biopsy samples and a lack of standardization might hinder its full predictive value in this cancer. Objectives: In order to better understand the current practices of histological grading in HCC, we examined the latest publications addressing its impact on the outcome of patients following surgical treatment. Methods: We searched the PubMed (MEDLINE) database under the headings “hepatocellular carcinoma”, “grade OR grading”, and “prognosis”. Qualitative and quantitative assessment of publications was performed according to the reference they used to grade their tumors (e.g. Edmondson-Steiner, World Health Organization). Results: We reviewed a total of 216 articles: 114 enclosed adequate information and were included herein. Among those, we found divergences as well as inaccuracies in the histological grade assessment of this cancer, which might have led to a non-standardized grade distribution, with further impact on data analysis. Nevertheless, in most of them, poor tumor differentiation correlated with worse prognosis, expressed by lower overall and/or disease-free survival. Conclusions: While histological grading of HCC has an important prognostic role, there is an unsatisfactory heterogeneity on the microscopic assessment of this tumor, urging for a movement towards standardization.

1 July 2014 in Annals of Hepatology
Verified
Journal Article
Open access
DPDenise C. Paranaguá-Vezozzo
Denise C. Paranaguá-Vezozzo
SOSuzane K. Ono
Suzane K. Ono
MAMónica V. Alvarado-Mora
Mónica V. Alvarado-Mora
AFAlberto Q. Farias
Alberto Q. Farias
MCMarione Cunha-Silva
Marione Cunha-Silva
FCFlair José Carrilho
Flair José Carrilho
The lack of information about hepatocellular carcinoma (HCC) in Brazil weakens health policy in preventing deaths from the illness. The aim of this study was to establish the cumulative incidence and the risk factors for hepatocellular carcinoma development in patients under a surveillance program. 884 patients with compensated cirrhosis were prospectively followed up for at least five years, from August 1998 until August 2008, with at least one annual ultrasonography liver examination and serum alpha fetoprotein (AFP) measurement. Among 884 patients, 72 (8.1%) developed a tumor with a median follow up of 21.4 months. In the hepatocellular carcinoma group, hepatitis C virus infection was the major etiological factor (65.3%), 56.9% (41/72) were male and the mean average age was 57 ± 10 years. The annual incidence of hepatocellular carcinoma was 2.9%. 79.2% (57/72) of HCCs were detected within Milan Criteria, and the mean survival time was 52.3 months, significantly higher than for those outside Milan, with a mean time of 40.6 months (p = 0.0003). The annual incidence of HCC among this large series of Brazilian cirrhotic patients was around 2.9% with a detection rate of 8.1%, or a cumulative incidence rate over five years of 14.3%. The three variables related to HCC risk were low serum albumin [HR: 0.518 (0.46-0.78)], high AFP > 20 ng/mL [HR: 3.16 (1.86-5.38)], and ethnicity (Brazilian-East Asian descendants vs. other mixed Brazilian ethnicities) [HR: 2.86 (1.48-5.53)].

1 January 2018 in Clinics
Verified
Journal Article
Open access
VAVenancio A.F. Alves
Venancio A.F. Alves
KKKennichi Kakudo
Kennichi Kakudo
VLVirginia LiVolsi
Virginia LiVolsi
RLRicardo V. Lloyd
Ricardo V. Lloyd
YNYuri E. Nikiforov
Yuri E. Nikiforov
LTLester D. R. Thompson
Lester D. R. Thompson

1 March 2015 in Clinics
Verified
Journal Article
Open access
PDF file
ACAline Lopes Chagas
Aline Lopes Chagas
LKLuciana Kikuchi
Luciana Kikuchi
PHPaulo Herman
Paulo Herman
RARegiane S.S.M. Alencar
Regiane S.S.M. Alencar
CTClaudia M. Tani
Claudia M. Tani
VAVenancio A.F. Alves
Venancio A.F. Alves
Key words: Fibrolamellar hepatocellular carcinoma; Liver cancer; Liver neoplasms; Hepatocellular carcinoma (fibrolamellar variant)